Why AI matters at this scale

City of Hope is a premier, independent nonprofit clinical research center and hospital specializing in cancer treatment, diabetes, and other life-threatening diseases. Founded in 1913 and based in Duarte, California, it operates as a National Cancer Institute-designated comprehensive cancer center. With over 10,000 employees, it integrates cutting-edge research with a large clinical delivery system, including a network of community clinics. Its mission focuses on transforming the future of health through pioneering science and patient-centered care.

For an organization of this size and complexity, AI is not a luxury but a strategic imperative. The convergence of massive, high-dimensional data—from electronic health records (EHRs) and genomic sequencing to medical imaging and clinical trials—creates an unparalleled opportunity to derive insights human analysis alone cannot achieve. At a 10,000+ employee scale, even marginal efficiency gains in operations or clinical throughput can translate into millions in savings and expanded patient access. More critically, in oncology, where treatment personalization is key, AI can accelerate the path from discovery to delivery, potentially improving survival rates and quality of life.

Concrete AI Opportunities with ROI Framing

1. Precision Oncology Decision Support: Developing an AI platform that integrates genomic, proteomic, imaging, and clinical data can recommend personalized treatment regimens. The ROI includes improved patient outcomes (a core mission metric), reduced trial-and-error prescribing (lowering costs of ineffective therapies), and strengthened competitive positioning as a leader in precision medicine. Initial investment in data infrastructure and model development can be offset by more efficient use of high-cost targeted therapies and biologics.

2. Automated Clinical Trial Matching: Manually screening patient records for trial eligibility is slow and inefficient, leading to low enrollment rates. An NLP-based system can automatically parse unstructured clinical notes and match patients to open trials in real-time. The ROI is direct: faster trial accrual speeds up research timelines, generates more research revenue, and brings new therapies to market sooner. It also enhances patient care by providing access to cutting-edge treatments.

3. Predictive Operations Management: Machine learning models can forecast patient admission rates, predict surgical case durations, and optimize inventory for expensive pharmaceuticals. For a large hospital system, this can significantly reduce overtime costs, improve OR utilization, and minimize drug waste. The ROI is primarily financial, with hard savings from operational efficiencies that can be reinvested in research and care.

Deployment Risks Specific to This Size Band

Large, research-driven healthcare institutions like City of Hope face unique AI deployment challenges. Data Silos and Interoperability: Research data (genomics, trial results) often resides in separate systems from clinical EHRs, requiring significant integration effort. Regulatory and Compliance Hurdles: Any clinical AI tool may be subject to FDA scrutiny as a medical device, and all data use must strictly comply with HIPAA and patient consent protocols. Change Management at Scale: Rolling out new AI tools across thousands of clinicians and staff requires extensive training, workflow redesign, and proof of clinical utility to gain trust. High Stakes of Failure: In oncology, an erroneous AI recommendation could have severe consequences, necessitating rigorous validation, transparency, and human-in-the-loop safeguards that can slow deployment.